

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07D 307/82, A61K 31/34, A61P 29/00		A1	(11) International Publication Number: WO 00/69842
		(43) International Publication Date: 23 November 2000 (23.11.00)	
(21) International Application Number: PCT/EP00/04010 (22) International Filing Date: 4 May 2000 (04.05.00) (30) Priority Data: 9911452.2 17 May 1999 (17.05.99) GB (71) Applicant (for all designated States except US): BAYER AKTIENGESELLSCHAFT [DE/DE]; D-51368 Leverkusen (DE). (72) Inventors; and (75) Inventors/Applicants (for US only): BRÄUNLICH, Gabriele [DE/DE]; Claudiusweg 9, D-42115 Wuppertal (DE). ES-SAYED, Mazen [DE/DE]; Ricarda-Huch-Str. 36, D-40764 Langenfeld (DE). FISCHER, Rüdiger [DE/DE]; Zu den Fussfällen 23, D-50259 Pulheim (DE). FUGMANN, Burkhard [DE/DE]; Dr.-Kessel-Str. 3, D-40878 Ratingen (DE). HENNING, Rolf [DE/DE]; Am Jagdhaus 115, D-42113 Wuppertal (DE). SCHNEIDER, Stephan [DE/DE]; Am Ringofen 46, D-42327 Wuppertal (DE). SPERZEL, Michael [DE/DE]; Normannenstr. 31, D-42275 Wuppertal (DE). SCHLEMMER, Karl-Heinz [DE/DE]; Wildsteig 22a, D-42113 Wuppertal (DE). STURTON, Graham [GB/GB]; 184 Windsor Road, Bray Maidenhead SL6 2DW (GB). FITZGERALD, Mary [GB/GB]; 2 Pater-		noster Court, Cassington Road Yarton, Oxon OX5 1 QB (GB). BRIGGS, Barbara [GB/GB]; 24 Latchmere Road, Kingston-upon-Thames, Surrey KT2 5TW (GB). CONCEPCION, Amel [PH/JP]; 3-6-27-207, Shibatsuji-cho, Nara City, Nara 630-8114 (JP). BULLOCK, William [US/US]; 60 Hermann Lane, Easton, CT 06612 (US). (74) Common Representative: BAYER AKTIENGESELLSCHAFT; D-51368 Leverkusen (DE). (81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
		Published With international search report.	
(54) Title: BENZOFURANYLSULFONATES			
<div style="text-align: center;"> <p>(I)</p> </div>			
(57) Abstract <p>The invention relates to Benzofuranylsulfonates of general formula (I) their preparation and their use for the treatment of inflammatory processes.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Benzofuranylsulfonates

The invention relates to Benzofuranylsulfonates, processes for their preparation and their use in medicaments.

5


It is known that the NADPH oxidase of phagocytes is the physiological source to the superoxide radical anion and reactive oxygen species derived therefrom which are important in the defence against pathogens. Moreover, both inflammatory (e.g. $\text{TNF}\alpha$, IL-1 or IL-6) and anti-inflammatory cytokines (e.g. IL-10) play a pivotal role in host defence mechanism. Uncontrolled production of inflammatory mediators can lead to acute or chronic inflammation, auto immune diseases, tissue damage, multi-organ failure and to death. It is additionally known that elevation of phagocyte cyclic AMP leads to inhibition of oxygen radical production and that this cell function is more sensitive than others such as aggregation or enzyme release.

15

Benzofuran derivatives having phosphodiesterase IV (PDE IV)-inhibiting action are described in the publication EP 731 099. The reference describes only one methane-sulfonic acid ester, however.

20

In order to provide alternative compounds of similar or improved PDE IV-inhibitory activity, the present invention relates to Benzofuranylsulfonates of the general formula (I)



in which

25

A represents hydrogen, straight-chain or branched acyl or alkoxycarbonyl, each having up to 6 carbon atoms, halogen, carboxyl, cyano, nitro, hydroxyl, trifluoromethyl or trifluoromethoxy, or straight-chain or branched alkyl having

up to 6 carbon atoms, which is optionally substituted by carboxyl, alkoxy or alkoxycarbonyl each having up to 4 carbon atoms, phenoxy or benzoyl,

5 R^1 represents hydrogen, straight-chain or branched alkyl having up to 4 carbon atoms, an amino protecting group or a group of the formula $-CO-R^5$

in which

10 R^5 denotes straight chain or branched alkoxy having up to 4 carbon atoms,

R^2 and R^3 are identical or different and represent hydrogen, cycloalkyl having up to 6 carbon atoms, straight chain or branched alkyl, alkoxycarbonyl or alkenyl each having up to 8 carbon atoms,

15 or

R^2 and R^3 together with the nitrogen atom form a 5- to 7-membered saturated heterocycle optionally having a further O atom,

20 R^4 represents aryl having 6 to 10 carbon atoms or
represents a 5 to 7 membered, aromatic, saturated or unsaturated heterocycle,
which can contain up to 3 oxygen, sulphur and/or nitrogen atoms as hetero-
atoms or a residue of a formula $-NR^6$,

25 wherein

R^6 denotes hydrogen or straight-chain or branched alkyl or alkoxycarbonyl
each having up to 6 carbon atoms,

30 and to which further a benzene ring can be fused and wherein aryl and/or the
heterocycle are optionally monosubstituted to trisubstituted by identical or

different substituents from the series comprising hydroxyl, halogen, nitro, 1H-tetrazolyl, pyridyl, trifluoromethyl, trifluoromethoxy, difluoromethyl, difluoromethoxy, cyano, carboxy, straight-chain or branched alkoxy, alkoxycarbonyl or acyl each having up to 6 carbon atoms or by straight-chain or branched alkyl having up to 5 carbon atoms, which is optionally substituted by carboxyl or straight-chain or branched alkoxycarbonyl having up to 4 carbon atoms or by a group of formula $-NR^7R^8$, $-SR^9$, $-(NH)_a-SO_2R^{10}$ or $-O-SO_2R^{11}$,

in which

R^7 and R^8 are identical or different and denote hydrogen or a straight-chain or branched alkyl having up to 4 carbon atoms,

or

R^7 denotes hydrogen

and

R^8 denotes straight-chain or branched acyl having up to 6 carbon atoms


R^9 denotes hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms,

a denotes a number 0 or 1,

R^{10} and R^{11} are identical or different and represent straight-chain or branched alkyl having up to 6 carbon atoms, benzyl or phenyl, which are optionally substituted by trifluoromethyl, halogen or straight-chain or branched alkyl having up to 4 carbon atoms,

L represents an oxygen or sulfur atom,

D represents a residue of a formula



10 or aryl having 6 to 10 carbon atoms or a 5 to 7-membered aromatic, saturated or unsaturated heterocycle having up to 3 heteroatoms from the series comprising N, S and O and to which a phenyl ring can be fused, wherein all abovementioned residues and ring systems are optionally monosubstituted to trisubstituted by halogen, carboxyl, straight-chain or branched alkyl or alkoxy carbonyl each having up to 6 carbon atoms, pyridyl and/or by a residue of a formula $-NR^{12}-E-R^{13}$, $-NR^{14}-CO-NR^{15}R^{16}$, $-NR^{17}-SO_2-NR^{18}R^{19}$, $-SO_2-R^{20}$ or $-(SO_2)_b-NR^{21}R^{22}$,

15

wherein

b denotes a number 0 or 1,

20

E denotes a residue of formula SO_2 or CO

R^{12} , R^{14} , R^{15} , R^{16} , R^{17} , R^{18} , R^{19} , R^{21} and R^{22} are identical or different and denote hydrogen, phenyl or straight-chain or branched alkyl having up to 6 carbon atoms,


25

R^{13} denotes straight-chain or branched alkyl or alkoxy each having up to 6 carbon atoms,

R^{20} denotes benzyl, phenyl, pyridyl or straight-chain or branched alkyl having up to 6 carbon atoms,

5 or

D represents straight-chain or branched alkyl or alkenylen having up to 8 carbon atoms, which are monosubstituted to trisubstituted by halogen, aryl having 6 to 10 carbon atoms or a 5 to 7-membered saturated or unsaturated heterocycle having up to 3 heteroatoms from the series comprising N, S and O and to which a phenyl ring can be fused or by a residue of a formula $-NR^{23}R^{24}$ or



wherein

15

R^{23} and R^{24} have the abovementioned meaning of R^{15} and R^{16} and are identical or different to the latter,

20

wherein the abovementioned ring systems are optionally substituted by halogen,

and in the case that

R^4 does not represent phenyl or substituted phenyl,

25

D in addition can represent benzyl or straight-chain or branched alkyl having up to 5 carbon atoms,

or

D optionally represents a residue of a formula $-NR^{25}R^{26}$

wherein

5

R^{25} and R^{26} have the abovementioned meaning of R^{21} and R^{22} and are identical or different to the latter,

and salts thereof.

10

The benzofuranylsulfonates according to the invention can also be present in the form of their salts. In general, salts with organic or inorganic bases or acids may be mentioned here.

15

Physiologically acceptable salts are preferred in the context of the present invention. Physiologically acceptable salts of the Benzofuranylsulfonates can be metal or ammonium salts of the substances according to the invention, which contain a free carboxylic group. Those which are particularly preferred are, for example, sodium, potassium, magnesium or calcium salts, and also ammonium salts which are derived from ammonia, or organic amines, such as, for example, ethylamine, di- or triethylamine, di- or triethanolamine, dicyclohexylamine, dimethylaminoethanol, arginine, lysine or ethylenediamine.

20

25

Physiologically acceptable salts can also be salts of the compounds according to the invention with inorganic or organic acids. Preferred salts here are those with inorganic acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid or sulphuric acid, or salts with organic carboxylic or sulphonic acids such as, for example, acetic acid, maleic acid, fumaric acid, malic acid, citric acid, tartaric acid, ethanesulphonic acid, benzenesulphonic acid, toluenesulphonic acid or naphthalenedisulphonic acid.

30

The compounds according to the invention can exist in stereoisomeric forms which either behave as image and mirror image (enantiomers), or which do not behave as image and mirror image (diastereomers). The invention relates both to the antipodes and to the racemate forms, as well as to individual diastereomers and to the diastereomer mixtures. The racemate forms, like the diastereomers, can be separated into the stereoisomerically uniform constituents in a known manner.

Heterocycle in general represents a 5- to 7-membered, aromatic, saturated or unsaturated, preferably 5- to 6- membered, aromatic, saturated or unsaturated ring which can contain up to 3 oxygen, sulphur and/or nitrogen atoms as heteroatoms and to which further aromatic rings can be fused.

The following are mentioned as preferred: thienyl, furyl, pyrrolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, quinolyl, isoquinolyl, quinazolyl, quinoxazolyl, thiazolyl, dihydrothiazolyl, benzothiazazolyl, isothiazolyl, benzisothiazolyl, oxazolyl, benzoxazolyl, isoxazolyl, imidazolyl, benzimidazolyl, indolyl, morpholinyl, pyrrolidinyl, piperidyl, piperazinyl, oxazolinyl or triazolyl.

Preferred compounds of the general formula (I) are those

in which

A represents hydrogen, halogen, carboxyl, cyano, nitro, hydroxyl, trifluoromethyl, trifluoromethoxy or alkoxy having up to 4 carbon atoms

R¹ represents hydrogen, straight-chain or branched alkyl having up to 4 carbon atoms or a group of the formula -CO-R⁵

in which

R⁵ denotes straight chain or branched alkoxy having up to 4 carbon atoms,

R² and R³ are identical or different and represent hydrogen, cyclobutyl, cyclopentyl, cyclohexyl or straight-chain or branched alkyl, alkoxycarbonyl or alkenyl each having up to 4 carbon atoms, or

5

or

R² and R³ together with the nitrogen atom form a pyrrolidinyl-, piperidinyl- or morpholinyl-ring,

10

and


R⁴ represents phenyl, pyridyl or thienyl, wherein all rings are optionally monosubstituted to trisubstituted by identical or different substituents from the series comprising hydroxyl, fluorine, chlorine, bromine, nitro, carboxy, straight-chain or branched alkoxy, alkoxycarbonyl or acyl each having up to 3 carbon atoms, or by straight-chain or branched alkyl having up to 3 carbon atoms, which is optionally substituted by carboxyl or straight-chain or branched alkoxycarbonyl having up to 3 carbon atoms

15

20

L represents an oxygen or sulfur atom,

D represents a residue of a formula



or phenyl, pyridyl, thienyl, furyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, imidazolyl, morpholinyl, piperidinyl, pyrrolidinyl or piperazinyl, wherein all

5 abovementioned residues and ring systems are optionally monosubstituted to trisubstituted by halogen, carboxyl, straight-chain or branched alkyl or alkoxy carbonyl each having up to 4 carbon atoms, pyridyl and/or by a residue of a formula $-NR^{12}E-R^{13}$, $-NR^{14}CO-NR^{15}R^{16}$, $-NR^{17}SO_2-NR^{18}R^{19}$, $-SO_2-R^{20}$ or $-(SO_2)_b-NR^{21}R^{22}$,

wherein

10 b denotes a number 0 or 1,

E denotes a residue of formula SO_2 or CO


15 R^{12} , R^{14} , R^{15} , R^{16} , R^{17} , R^{18} , R^{19} , R^{21} and R^{22} are identical or different and denote hydrogen, phenyl or straight-chain or branched alkyl having up to 4 carbon atoms,

R^{13} denotes straight-chain or branched alkyl or alkoxy each having up to 4 carbon atoms,

20 R^{20} denotes benzyl, phenyl, pyridyl, ethyl or methyl,

or

25 D represents straight-chain or branched alkyl or alkenylene having up to 6 carbon atoms, which are monosubstituted to trisubstituted by halogen, phenyl, pyridyl, thienyl, furyl, imidazolyl, morpholinyl, piperidinyl, pyrrolidinyl, piperazinyl or by a residue of a formula $-NR^{23}R^{24}$ or



wherein

5 R^{23} and R^{24} have the abovementioned meaning of R^{15} and R^{16} and are identical or different to the latter,

wherein the abovementioned ring systems are optionally substituted by halogen,

and in the case that

10

R^4 does not represent phenyl or substituted phenyl,

D in addition can represent benzyl or straight-chain or branched alkyl having up to 4 carbon atoms,

15

or

D optionally represents a residue of a formula $-NR^{25}R^{26}$

20

wherein

R^{25} and R^{26} have the abovementioned meaning of R^{21} and R^{22} and are identical or different to the latter,

25

and salts thereof.

Particularly preferred compounds of the general formula (I) are those

in which

A, R² and R³ represent hydrogen,

- 5 R¹ represents hydrogen or straight-chain or branched alkyl having up to 3 carbon atoms or a group of the formula -CO-R⁵,

in which


- 10 R⁵ denotes straight chain or branched alkoxy having up to 3 carbon atoms,

R⁴ represents phenyl or pyridyl, which are optionally up to difold substituted by identical or different substituents from the series fluorine, chlorine, methyl or methoxy,

15

L represents an oxygen atom,

D represents a residue of a formula



or phenyl, pyridyl, thienyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, imidazolyl, morpholinyl, piperidinyl, pyrrolidinyl or piperazinyl, wherein all abovementioned residues and ring systems are optionally monosubstituted to

25 trisubstituted by halogen, carboxyl, straight-chain or branched alkyl or alkoxy carbonyl each having up to 3 carbon atoms, pyridyl and/or by a residue of a formula -NR¹²-E-R¹³, -NR¹⁴-CO-NR¹⁵R¹⁶, -NR¹⁷-SO₂-NR¹⁸R¹⁹, -SO₂-R²⁰ or -(SO₂)₆-NR²¹R²²,

wherein

b denotes a number 0 or 1,

E denotes a residue of formula SO_2 or CO


R^{12} , R^{14} , R^{15} , R^{16} , R^{17} , R^{18} , R^{19} , R^{21} and R^{22} are identical or different and denote hydrogen, phenyl or straight-chain or branched alkyl having up to 3 carbon atoms,

R^{13} denotes straight-chain or branched alkyl or alkoxy each having up to 3 carbon atoms,

R^{20} denotes benzyl, phenyl or methyl,

or

D represents straight-chain or branched alkyl or alkenylen having up to 4 carbon atoms, which are monosubstituted to trisubstituted by halogen, phenyl, pyridyl, thienyl, furyl, imidazolyl, morpholinyl, piperidinyl, pyrrolidinyl, piperazinyl or by a residue of a formula $-\text{NR}^{23}\text{R}^{24}$ or



wherein

R^{23} and R^{24} have the abovementioned meaning of R^{15} and R^{16} and are identical or different to the latter,

wherein the abovementioned ring systems are optionally substituted by halogen,

and in the case that

5

R^4 does not represent phenyl or substituted phenyl,

D in addition can represent benzyl or straight-chain or branched alkyl having up to 3 carbon atoms,

10

or

D optionally represents a residue of a formula $-NR^{25}R^{26}$

15

wherein

R^{25} and R^{26} have the abovementioned meaning of R^{21} and R^{22} and are identical or different to the latter


20

and salts thereof.

A process for the preparation of the compounds of the general formula (I) has additionally been found, characterized in that

25


compounds of the general formula (II)



in which

A, L, R¹, R², R³ and R⁴ have the abovementioned meaning

5 are reacted with compounds of the general formula (III)




in which

10 D has the abovementioned meaning,

in inert solvents, if appropriate in the presence of a base and/or in the presence of an auxiliary.

15 The process according to the invention can be illustrated by way of example by the following equation:



Suitable solvents are generally customary organic solvents which do not change under the reaction conditions. These include ethers such as diethyl ether, dioxane or tetrahydrofuran. Tetrahydrofuran is preferred.

5 Suitable bases and auxiliaries are generally organic bases. Organic amines (trialkyl- (C_1-C_6) amines) such as triethylamine, or heterocycles such as 1,4-diazabicyclo[2.2.2]octane (DABCO), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) or 4-dimethylaminopyridine. Triethylamine and 4-dimethylaminopyridine are preferred.

10 The base is employed in an amount from 1 mol to 10 mol, preferably from 1.0 mol to 4 mol, relative to 1 mol of the compounds of the general formula (III).

In case 4-dimethylaminopyridine is employed, the base is used in a catalytic amount.

15 The auxiliary is employed in an amount from 1 mol to 10 mol, preferably from 1.0 mol to 4 mol, relative to 1 mol of the compounds of the general formula (III).


The process is in general carried out in a temperature range from -30°C to $+30^{\circ}\text{C}$, preferably from -10°C to $+20^{\circ}\text{C}$.

20

The process is generally carried out at normal pressure. However, it is also possible to carry it out at elevated pressure or at reduced pressure (for example in a range from 0.5 to 5 bar).

25 The compounds of the general formula (II) are known or as species new and can be prepared characterized in that

[A] first compounds of the general formula (IV)




in which

A and R⁴ have the abovementioned meaning,

5

are reacted with a catalytic amount of base, such as alkali alcoholates, preferred sodium ethanolate to compounds of the general formula (V)



10 in which

A and R⁴ have the abovementioned meaning,

followed by reaction with compounds of the general formula (VI)


15



in which

20 R² has the abovementioned meaning,

in inert solvents, if appropriate in the presence of a base and/or in the presence of an auxiliary to compounds of a general formula (VII)



in which


A, L, R² und R⁴ have the abovementioned meaning,

5

and in a last step the benzyl group is removed by hydrogenation,

or

10 [B] compounds of the general formula (VIII)



in which

15 A, R¹ and R⁴ have the abovementioned meaning

are reacted with compounds of the general formula (VI)



20

in which

L and R² have the abovementioned meaning,

in inert solvents, if appropriate in the presence of a base

and in the case of $R^2/R^3 = H$ and $L = O$,

5 compounds of the general formula (V) or (VIII) are reacted with compounds of the general formula (IX)



10 in which

E denotes halogen, preferably chlorine,

and in the case of $R^2/R^3 = H$ and $L = S$,

15

compounds of the general formula (V) or (VIII) are reacted with NH_4SCN ,

and in case of R^1 , R^2 and/or $R^3 \neq H$ the free amino groups are derivated optionally by common methods.

20

Suitable solvents for the first step of the procedure [A] (IV-V) are generally alcohols such as methanol, ethanol or propanol. Ethanol is preferred.

25 Suitable bases for the first step are general bases, such as alkali alcoholates, e.g. sodium methanolate, sodium ethanolate or sodium propanolate. Sodium ethanolate is preferred.

The base is employed in catalytic amounts.

30 The process is in general carried out in a temperature range from $0^\circ C$ to $60^\circ C$, preferably at room temperature.

The process is generally carried out at normal pressure. However, it is also possible to carry out it at elevated pressure or at reduced pressure (for example in a range from 0.5 to 5 bar).

5

Suitable solvents for the second step of the procedure [A] (V - VII) are generally customary organic solvents which do not change under the reaction conditions. These include ethers such as diethyl ether, dioxane or tetrahydrofuran, dimethylsulfoxide, dimethylformamide, halogenohydrocarbons such as dichloromethane, trichloromethane or tetrachloromethane. Dichloromethane is preferred.

10

The process is in general carried out in a temperature range from -30°C to +40°C, preferably from -10°C to room temperature.

15

The process is generally carried out at normal pressure. However, it is also possible to carry out it at elevated pressure or at reduced pressure (for example in a range from 0.5 to 5 bar).

20

The hydroxyl-protective group is in general removed with hydrogen in ethylacetate, diethyl ether or tetrahydrofuran. Suitable catalysts are noble metal catalysts, preferably palladium and palladium on charcoal.

25


Suitable solvents for the procedure [B] are generally customary organic solvents which do not change under the reaction conditions. These include ethers such as diethyl ether, dioxane or tetrahydrofuran, dimethylsulfoxide, dimethylformamide or halogenohydrocarbons such as dichloromethane, trichloromethane or tetrachloromethane. Dichloromethane is preferred.

30

The process is in general carried out in a temperature range from -30°C to +100°C, preferably from -10°C to +50°C.

The process is generally carried out at normal pressure. However, it is also possible to carry out it at elevated pressure or at reduced pressure (for example in a range from 0.5 to 5 bar).

- 5 The compounds of the general formula (IV) are as species new and can be prepared by reaction of compounds of the general formula (X)




in which

10

A has the abovementioned meaning,

with hydroxylamine hydrochloride in a presence of sodium formiate to compounds of the general formula (XI)




15

in which

A has the abovementioned meaning,

- 20 followed by reaction with compounds of the general formula (XII)



in which

25

R⁴ has the abovementioned meaning,

and

T represents halogen, preferably bromine,

5

in inert solvents and in the presence of a base.

Suitable solvents are generally customary organic solvents which do not change under the reaction conditions. These include ethers such as diethyl ether, dioxane or
10 tetrahydrofuran, acetone, dimethylsulfoxide, dimethylformamide or alcohols such as methanol, ethanol, propanol or halogenohydrocarbons such as dichloromethane, trichloromethane or tetrachloromethane. Acetone and dimethylformamide are preferred.

Suitable bases for the procedure are generally inorganic or organic bases. These
15 preferably include alkali metal hydroxides such as, for example, sodium hydroxide or potassium hydroxide, alkaline earth metal hydroxides such as, for example, barium hydroxide, alkali metal carbonates such as sodium carbonate, potassium carbonate, alkaline earth metal carbonates such as calcium carbonate. Potassium carbonate (powdered) is preferred.

20

The base is employed in an amount from 1 mol to 10 mol, preferably from 1.0 mol to 4 mol, relative to 1 mol of the compounds of the general formulae (XI).

The process is in general carried out in a temperature range from -30°C to +100°C,
25 preferably from -10°C to +60°C.

The process is generally carried out at normal pressure. However, it is also possible to carry out it at elevated pressure or at reduced pressure (for example in a range from 0.5 to 5 bar).

30

The compounds of the general formula (X) are known or as species new and be can prepared by reaction of 2,4-dihydroxy-benzaldehydes with benzylbromide in one of the abovementioned solvents and bases, preferably in acetone with potassium carbonate at room temperature.

5

The compounds of the general formulae (II), (IV), (VII), (IX) and (XI) are as species new and can be prepared like described above.

10

The compounds of the general formulae (III), (VI), (VIII), (IX) and (XII) are known or as species new and can be prepared by customary methods.

15

The compounds of the general formula (V) can be prepared like described above or in a single step procedure by reacting compounds of the general formula (XI) with compounds of the general formula (XII) in the presence of a surplus of sodium ethylate under reflux .

20

Surprisingly it was found that compounds given by the general formula (I) inhibited oxygen radical formation as well as $\text{TNF}\alpha$ (tumor necrosis factor) production, but potentiated the release of IL-10. These compounds elevated cellular cyclic AMP probably by inhibition of phagocyte phosphodiesterase activity.

25

The compounds according to the invention specifically inhibit the production of superoxide by polymorphonuclear leukocytes (PMN). Furthermore, these compounds inhibit $\text{TNF}\alpha$ release and potentiate IL-10 production in human monocytes in response to a variety of stimuli including bacterial lipopolysaccharide (LPS), complement-opsonized zymosan (ZymC3b) and IL-1 β .

30

The described effects are probably mediated by the elevation of cellular cAMP probably due to inhibition of the type IV phosphodiesterase responsible for its degradation.

They can therefore be employed in medicaments for the treatment of acute and chronic inflammatory processes.

5 The compounds according to the invention are preferably suitable for the treatment and prevention of acute and chronic inflammation and auto immune diseases, such as emphysema, alveolitis, shock lung, all kinds of asthma, COPD, ARDS, bronchitis, arteriosclerosis, arthrosis, inflammations of the gastro-intestinal tract, rheumatoid arthritis, myocarditis, sepsis and septic shock, arthritis, rheumatoid spondylitis and osteoarthritis, gram negative sepsis, toxic shock syndrome, acute respiratory distress
10 syndrome, bone resorption diseases, reperfusion injury, graft vs host reaction, allograft rejection, malaria, myalgias, HIV, AIDS, cachexia, Crohn's disease, ulcerative colitis, pyresis, system lupus erythematosus, multiple sclerosis, type I diabetes mellitus, psoriasis, Bechet's disease, anaphylactoid purpura nephritis, chronic glomerulonephritis, inflammatory bowel disease and leukemia. The compounds according to
15 the invention are additionally suitable for reducing the damage to infarct tissue after reoxygenation. In this case the simultaneous administration of allopurinol to inhibit xanthine oxidase is of advantage. Combination therapy with superoxide dismutase is also of use.

20 Test description

1. Preparation of human PMN

Blood was taken from healthy subjects by venous puncture and neutrophils were purified by dextran sedimentation and resuspended in the buffered
25 medium.

2. Inhibition of FMLP-stimulated production of superoxide radical anions.

Neutrophils ($2.5 \times 10^5 \text{ ml}^{-1}$) were mixed with cytochrome C (1.2 mg/ml) in the wells of a microtitre plate. Compounds according to the invention were added
30 in dimethyl sulphoxide (DMSO). Compound concentration ranged from 2.5 nM to 10 μM , the DMSO concentration was 0.1% v/v in all wells. After addition of

cytochalasin b ($5 \mu\text{g} \times \text{ml}^{-1}$) the plate was incubated for 5 min at 37°C . Neutrophils were then stimulated by addition of $4 \times 10^{-8} \text{ M}$ FMLP and superoxide generation measured as superoxide dismutase inhibitable reduction of cytochrome C by monitoring the OD_{550} in a microtitre plate spectrophotometer, e.g. a thermomax microtitre plate spectrophotometer. Initial rates were calculated using a kinetic calculation programme such as a softmax programme. Blank wells contained 200 units of superoxide dismutase.

The inhibition of superoxide production was calculated as follows:

$$\frac{[1 - ((\text{Rx} - \text{Rb}))]}{((\text{Ro} - \text{Rb}))} \cdot 100 = \% \text{ inhibition}$$

Rx = Rate of the well containing the compound according to the invention.

Ro = Rate in the control well.

Rb = Rate in the superoxide dismutase containing blank well.

Compounds according to the invention have IC_{50} values in the range $0.001 \mu\text{M}$ - $1 \mu\text{M}$ (see Table A).

3. Measurement of PMN cyclic AMP concentration

The compounds according to the invention were incubated with 3.7×10^6 PMN for 5 min at 37°C before addition of $4 \times 10^{-8} \text{ M}$ FMLP. After 6 min protein was precipitated by the addition of 1% v/v conc. HCl in 96% v/v ethanol containing 0.1 mM EDTA. After centrifugation the ethanolic extracts were evaporated to dryness under N_2 and resuspended in 50 mM Tris/HCl pH 7.4 containing 4 mM EDTA. The cyclic AMP concentration in the extracts was determined using a cyclic AMP binding protein assay supplied by Amersham International plc. Cyclic AMP concentrations were expressed as percentage of vehicle containing control incubations.

Compounds elavate the cAMP-level at 1 μ M compound 0-400% of control values.

4. Assay of PMN phosphodiesterase

5 This was performed as a particulate fraction from human PMN essentially as described by Souness and Scott (Biochem. J. 291, 389-395, 1993). Particulate fractions were treated with sodium vanadate / glutathione as described by the authors to express the descrete stereospecific site on the phosphodiesterase enzyme. Compounds according to the invention had IC_{50} values ranging from 10 0,001 μ M to 1 μ M (see Table A).

5. Assay of human platelet phosphodiesterase

This was performed essentially as described by Schmidt et al. (Biochem. Pharmacol. 42, 153-162, 1991) except that the homogenate was treated with 15 vanadate glutathione as above. Compounds according to the invention had IC_{50} values greater than 100 μ M.

6. Assay of binding to the rolipram binding site in rat brain membranes

20 This was performed essentially as described by Schneider et al. (Eur. J. Pharmacol. 127, 105-115, 1986). Compounds according to the invention had IC_{50} values in the range 0,01 to 10 μ M.

7. Preparation of human monocytes

25 Blood was taken from normal donors. Monocytes were isolated from peripheral blood by density centrifugation, followed by centrifugal elutriation.

8. Endotoxin induced TNF release

30 Monocytes (1×10^6 ml^{-1}) were stimulated with LPS ($2 \mu g$ ml^{-1}) and coincubated with the compounds at different concentrations (10^{-4} to $10 \mu g$ ml^{-1}). Compounds were dissolved in DMSO/medium (2% v/v). The cells were incubated in RPMI-1640 medium glutamine/FCS supplemented and at 37°C in a humidified

atmosphere with 5% CO₂. After 18 to 24 hours TNF was determined in the supernatants by an human TNF specific ELISA (medgenix). Controls were nonstimulated and LPS stimulated monocytes without compounds.

- 5 9. Endotoxin induced shock lethality in mice
- B6D2F1 mice (n=10) were sensitized with galactosamine (600 mg/kg), and shock and lethality were triggered by LPS (0.01 µg/mouse). The compounds were administered intravenously 1 hour prior LPS. Controls were LPS challenged mice without compound. Mice were dying 8 to 24 hours post LPS challenge.
- 10

The galactosamine / LPS mediated mortality was reduced.

10. Stimulation of human monocytes and determination of cytokine levels
- 15 Human monocytes (2x10⁵ in 1 ml) were stimulated with 100 ng/ml LPS, 0.8 mg/ml zymC3b or 10 ng/ml IL-1β in the presence of test compounds. The final DMSO concentration was maintained at 0.1 % v/v. Cells were incubated overnight in a humidified atmosphere of 5% CO₂ at 37°C. Supernatants were harvested and stored at -70°C. The TNFα concentration was measured by
- 20 ELISA using the A6 anti-TNF monoclonal antibody (Miles) as the primary antibody. The secondary antibody was the polyclonal anti-TNFα antibody IP300 (Genzyme) and the detection antibody was a polyclonal anti-rabbit IgG alkaline phosphatase conjugate (Sigma). IL-10 was determined by ELISA (Biosource).

Table A

Example No.	IC ₅₀ O ₂ ⁻ [μM]	IC ₅₀ PDE IV [μM]
13	0.065	0.021
21	0.02	0.04
24	0.06	0.13
36	0.007	0.001
46	0.035	0.006
47	0.02	0.033
49	0.001	0.001

5 The new active compounds can be converted in a known manner into the customary
formulations, such as tablets, coated tablets, pills, granules, aerosols, syrups, emulsions,
suspensions and solutions, using inert, nontoxic, pharmaceutically suitable excipients
or solvents. In this connection, the therapeutically active compound should in each case
be present in a concentration of about 0.5 to 90% by weight of the total mixture, i.e. in
10 amounts which are sufficient in order to achieve the dosage range indicated.

The formulations are prepared, for example, by extending the active compounds with
solvents and/or excipients, if appropriate using emulsifiers and/or dispersants, where,
for example, in the case of the use of water as a diluent, organic solvents can be used as
15 auxiliary solvents if appropriate.

Administration is carried out in a customary manner, preferably orally or parenterally.

20 In the case of parenteral administration, solutions of the active compound can be
employed using suitable liquid vehicles.

In general, it has proved advantageous on intravenous administration to administer amounts from about 0.001 to 10 mg/kg, preferably about 0.01 to 5 mg/kg of body weight to achieve effective results, and on oral administration the dosage is about 0.01 to 25 mg/kg, preferably 0.1 to 10 mg/kg of body weight.

5

In spite of this, it may be necessary to depart from the amounts mentioned, in particular depending on the body weight or the type of application route, on individual behaviour towards the medicament, the manner of its formulation and the time or interval at which administration takes place. Thus, in some cases it may be sufficient to manage with less than the abovementioned minimum amount, while in other cases the upper limit mentioned must be exceeded. In the case of administration of relatively large amounts, it is advisable to divide these into several individual doses over the course of the day.

10

15


Solvents

	a	=	dichloromethane/methanol	15:1 (v/v)
	b	=	dichloromethane/methanol	20:1
5	c	=	dichloromethane/methanol	50:1
	d	=	dichloromethane/methanol	40:1
	e	=	ethylacetate/cyclohexane	5:1
	f	=	chloroform/methanol	10:1
	g	=	dichloromethane/methanol	10:1
10	h	=	dichloromethane/methanol	30:1
	i	=	chloroform/methanol	30:1
	j	=	chloroform/methanol/water/acetic acid	70:30:5:5
	k	=	dichloromethane/methanol/formic acid	9:1:0.1

15 **Starting compounds:****Example I**

4-Benzyloxy-2-hydroxybenzaldehyde

20



13.8 g (0.1 mol) 2,4-dihydroxybenzaldehyde are dissolved in 150 ml acetone, 17.1 g (0.1 mol) benzylbromide and 13.8 g (0.1 mol) potassium carbonate are added, and the mixture is stirred at room temperature for 3 d. After filtration, the solvent is removed in vacuo and the residual crude product further purified by column chromatography on silica gel using dichloromethane as eluent.


Yield: 9.2 g (40%)

m.p.: 81-82°C

¹H-NMR (CDCl₃, 400 MHz): δ = 5.11 (s, 2H; CH₂); 6.51 (d, 1H, Ar-H); 6.61 (dd, 1H, Ar-H); 7.32 - 7.45 (m, 6H, Ar-H); 9.82 (s, 1H, CHO); 11.60 (s, 1H, OH) ppm.

5 Example II

4-Benzyloxy-2-hydroxybenzonitrile



10

25.0 g (0.11 mol) of the compound of example I, 8.67 g (0.13 mol) hydroxylamine hydrochloride and 15.0 g (0.22 mol) sodium formate are dissolved in 170 ml formic acid, and the solution stirred under reflux for 1-3 h. The reaction mixture is cooled to room temperature, poured into ice/water and extracted with dichloromethane. The organic layer is dried (Na₂SO₄), the solvent removed in vacuo and the residue triturated with dichloromethane. Alternatively, the precipitate which is formed after dilution with ice/water is filtered off and dried in a desiccator in the presence of phosphorus pentoxide. The crude product is crystallized from dichloromethane/cyclohexane.


15

Yield: 15.0 g (61%)

20

m.p.: 135-136°C

¹H-NMR (400 MHz, DMSO-d₆): δ = 5.13 (s, 2H, CH₂); 6.58 (d, 1H, Ar-H); 6.60 (dd, 1H, Ar-H); 7.32 - 7.46 (m, 5H, Ar-H); 7.50 (d, 1H, Ar-H); 11.10 (br.s, 1H, OH) ppm.

Example III **ω -Bromo-2,4-dichloroacetophenone**

5

To a solution of 155.2 g (788 mmol) 2,4-dichloroacetophenone in 450 ml glacial acetic acid are added 40.4 ml (788 mmol) bromine at 50°C. After 1 h at 50°C, further 4 ml (78.8 mmol) bromine are added and the mixture is stirred for an additional hour. The solution is cooled to room temperature, concentrated to half of its volume and diluted with 800 ml water. The mixture is neutralized with solid sodium carbonate and extracted three times with ethyl acetate. The organic layer is dried (Na₂SO₄), the solvent removed in vacuo, finally under high vacuum. The crude product is used directly without further purification for the following reaction and stored in the meantime at -20°C.


10

Yield: 211.4 g (quant.); yellow oil

15

Example IV

20

3-Amino-2-(2,4-dichlorobenzoyl)-6-benzyloxy-benzofuran

Single step procedure:

10.0 g (44.0 mmol) of the compound of example II are dissolved in 200 ml ethanol, and 5.98 g (88.0 mmol) sodium ethylate and 15.4 g (48.0 mmol) of the compound of example III are added. The mixture is stirred under reflux for 4 d. During this time further 12.0 g sodium ethylate and 7.7 g of the compound of example III are added. The solvent is removed in vacuo and the residue is purified by column chromatography on silica gel (eluent: 1. dichloromethane, 2. dichloromethane/methanol 98:2).

Yield: 8.1 g (44%)


m.p.: 158°C

NMR-data see below.

Example IVa

Two step procedure:

a) ω -[(5-Benzyloxy-2-cyano)-phenoxy]-2,4-dichloroacetophenone:



To a mixture of 26.6 g (118 mmol) of the compound of example II and 48.85 g (354 mmol) powdered potassium carbonate in 800 ml acetone are added 34.8 g (130 ml) of the compound of example III under reflux. After a further 1-2 h under reflux, the mixture is filtered, the solvent evaporated in vacuo and the residue triturated using dichloromethane (1st crop of product) and dichloromethane/cyclohexane (4:1) (2nd crop of product).

Yield: 26.2 g (54%)

b) 3-Amino-2-(2,4-dichlorobenzoyl)-6-benzyloxy-benzofuran

5 To a solution of 37.5 g (91 mmol) of the compound of example IVa a) in 550 ml ethanol, three pellets of sodium hydroxide are added and the mixture is stirred at 50°C for 30 min. After cooling to room temperature, the mixture is filtered off (1st crop of product) and the filtrate is diluted with 300 ml of water. Most of the ethanol is removed in vacuo and the formed precipitate is filtered
10 (2nd crop of product).


Yield: 36.7 g (98%)

¹H-NMR (DMSO-d₆, 400 MHz): δ = 5.14 (s, 2H, CH₂); 6.97 (dd, 1H, Ar-H); 7.10 (d, 1H, Ar-H); 7.31 - 7.47 (m, 5H, Ar-H); 7.53 (br.s, 2H, NH₂); 7.57 (s, 2H, Ar-H); 7.75 (s, 1H, Ar-H); 7.93 (d, 1H, Ar-H); ppm.

15 Ms (EI): 411 (M⁺)

Example V

20 N-[2-(2,4-Dichlorobenzoyl)-6-benzyloxy-benzofuran-3-yl]urea



25 30.9 g (75 mmol) of the compound of example IV or IVa are dissolved in 750 ml dichloromethane and cooled to 0°C. 11.6 g (82 mmol) chlorosulfonyl isocyanate in

dichloromethane are added and the mixture is stirred at 0°C for 30 min and at room temperature for 3 h. The solvent is removed in vacuo, the residue suspended in water and stirred vigorously for 3 h at 60°C. After cooling to r.t. the suspension is filtered, the crude product dried in a desiccator in the presence of phosphorus pentoxide and triturated with diisopropylether at 40°C.

Yield: 33.7 g (98%)

m.p.: 192-193°C


¹H-NMR (DMSO-d₆, 400 MHz): δ = 5.18 (s, 2H, CH₂); 7.00 (dd, 1H, Ar-H); 7.05 (br.s, 2H, NH₂); 7.20 (d, 1H, Ar-H); 7.30 - 7.47 (m, 5H, Ar-H); 7.61 (dd, 1H, Ar-H); 7.68 (d, 1H, Ar-H); 7.82 (d, 1H, Ar-H); 8.37 (d, 1H, Ar-H); 9.71 (s, 1H, NH) ppm.

MS (FAB): 455 (M+H)⁺

The examples shown in Table B are prepared in analogy to the procedure for the compound of example V

Table B


structure



Ex.-No.	R ^I	R ^{II}	R ^{III}	R ^{IV}	Yield (% of theory)	R _f [*]
Va	OCH ₃	H	OCH ₃	H	69	0.30 ^{b)}
Vb	F	H	F	H	82	0.27 ^{d)}
Vc	Cl	H	H	H	90	0.18 ^{c)}
Vd	H	H	Cl	H	48	0.51 ^{b)}
Ve	Cl	H	H	Cl	92	0.47 ^{b)}
Vf	CH ₃	H	CH ₃	H	57	0.45 ^{b)}

Example VI

5 N-[2-(2,4-Dichlorobenzoyl)-6-hydroxy-benzofuran-3-yl]urea



To a solution of 5.0 g of the compound of example V in 100 ml THF are added 250 mg
10 10% palladium on activated charcoal, and the mixture is hydrogenated at atmospheric pressure and room temperature for 1-3 d. If necessary, further 125 mg 10% Pd/C are added and the hydrogenation is continued for 24 h. The mixture is filtered through celite and the solvent is removed in vacuo to about 1/3 of the original volume. Dichloromethane is added, the mixture is stirred at 0°C and the formed precipitate is
15 filtered off.

Yield: 4.0 g (quant.)

m.p.: 230-231°C


¹H-NMR (DMSO-d₆, 400 MHz): δ = 6.73 (d, 1H, Ar-H); 6.80 (dd, 1H, Ar-H); 7.03 (br.s, 2H, NH₂); 7.60 (dd, 1H, Ar-H); 7.65 (d, 1H, Ar-H); 7.80 (s, 1H, Ar-H); 8.30 (d, 1H, Ar-H); 9.72 (s, 1H, NH); 10.40 (br.s, 1H, OH) ppm.

MS (EI): 364 (M⁺).

Compounds shown in table I and II are prepared in analogy to example VI, characterized in that the corresponding 6-benzyloxy benzofuran is dissolved in
25 tetrahydrofuran and hydrogenated under atmospheric pressure in the presence of 10%

palladium on charcoal for 1-3 days. If necessary, further 10% Pd/C is added and hydrogenation is continued for 24 h. The mixture is filtered and the filtrate concentrated to about one third of the original volume until precipitation of product starts. An equal volume of dichloromethane is added, the mixture is stirred for 30 minutes, and the product is isolated by suction filtration. The filtrate is concentrated, re-dissolved in tetrahydrofurane, and dichloromethane added again at 0°C to yield a second crop of product.

Table I:



Ex.-No.	R ^I	R ^{II}	R ^{III}	R ^{IV}	Yield (% of th.)	R _f *
VII	F	H	F	H	90	0,76 j)
VIII	H	H	Cl	H	40	0,38 a)
IX	OCH ₃	H	OCH ₃	H	88	0,38 a)
X	Cl	H	H	H	91	0,36 a)
XI	Cl	H	H	Cl	91	0,31 b)
XII	CH ₃	H	CH ₃	H	58	0,26 b)

Table II:

Ex.-No.	Structure
XIII	

Preparation examples:

5

General procedure for the synthesis of the benzofuranyl sulfonates:

10 The corresponding 6-hydroxybenzofuran component is dissolved in dry tetrahydrofuran (with addition of dry N,N-dimethylformamide if necessary), and 1,5 - 2 mol equivalents triethylamine, 1,25 - 1,75 mol equivalents of the corresponding sulfonyl chloride and a catalytic amount of 4-dimethylaminopyridine are added successively at 0°C. The reaction mixture is stirred at room temperature overnight (or for several days if necessary) and concentrated. The residue is taken up in dichloromethane, chloroform or ethyl acetate, and repeatedly washed with water. The organic layer is dried over sodium sulfate and concentrated. The crude product is purified by trituration with a suitable solvent or by column chromatography over silica gel.

15

In analogy to the general procedure the following examples shown in table 1 are prepared:








































Table 1:











Ex. No.	D	R ^I	R ^{II}	R ^{III}	R ^{IV}	Yield (% of th.)	R _f *
1		Cl	H	Cl	H	75.9	0.52 ^{a)}
2		Cl	H	Cl	H	67	0.34 ^{b)}
3		Cl	H	Cl	H	32.7	0.25 ^{c)}
4		Cl	H	Cl	H	57.4	0.26 ^{b)}
5		Cl	H	Cl	H	80.4	0.49 ^{b)}
6		Cl	H	Cl	H	89.7	0.33 ^{d)}
7		Cl	H	Cl	H	83	0.52 ^{b)}
8		Cl	H	Cl	H	50.4	0.39 ^{a)}

Ex. No.	D	R ^I	R ^{II}	R ^{III}	R ^{IV}	Yield (% of th.)	R _f *
9		Cl	H	Cl	H	68	0.43 ^{a)}
10		Cl	H	Cl	H	70	0.61 ^{a)}
11		Cl	H	Cl	H	84.5	0.48 ^{b)}
12		F	H	F	H	88.5	0.21 ^{c)}
13		H	H	Cl	H	38.1	0.41 ^{d)}
14		OCH ₃	H	OCH ₃	H	33	0.54 ^{b)}
15		Cl	H	H	H	72.5	0.21 ^{c)}
16		OCH ₃	H	OCH ₃	H	65.4	0.48 ^{b)}
17		F	H	F	H	81.4	0.39 ^{b)}
18		Cl	H	H	H	76	0.45 ^{b)}
19		H	H	Cl	H	73.8	0.43 ^{b)}

Ex. No.	D	R ^I	R ^{II}	R ^{III}	R ^{IV}	Yield (% of th.)	R _f *
20		OCH ₃	H	OCH ₃	H	79	0.39 ^{a)}
21		Cl	H	Cl	H	77	0.49 ^{b)}
22		Cl	H	Cl	H	67	0.39 ^{b)}
23		OCH ₃	H	OCH ₃	H	60.4	0.28 ^{a)}
24		F	H	F	H	62.8	0.45 ^{a)}
25		Cl	H	H	H	68.7	0.54 ^{a)}
26		H	H	Cl	H	63.4	0.53 ^{a)}
27		F	H	F	H	88	0.28 ^{a)}

Ex. No.	D	R ^I	R ^{II}	R ^{III}	R ^{IV}	Yield (% of th.)	R _f *
28		Cl	H	H	H	53.4	0.32 ^{a)}
29		H	H	Cl	H	75	0.35 ^{a)}
30		Cl	H	Cl	H	76.6	0.59 ^{a)}
31		Cl	H	H	Cl	90	0.41 ^{a)}
32		Cl	H	H	Cl	85.2	0.57 ^{a)}
33		Cl	H	H	Cl	81.2	0.44 ^{b)}
34		Cl	H	H	Cl	84.4	0.37 ^{a)}
35		Cl	H	H	Cl	74	0.58 ^{a)}

Ex. No.	D	R ^I	R ^{II}	R ^{III}	R ^{IV}	Yield (% of th.)	R _f *
36		CH ₃	H	CH ₃	H	70	0.46 ^{d)}
37		CH ₃	H	CH ₃	H	72	0.48 ^{a)}
38		CH ₃	H	CH ₃	H	89	0.42 ^{b)}
39		CH ₃	H	CH ₃	H	81	0.34 ^{a)}
40		CH ₃	H	CH ₃	H	82.2	0.43 ^{a)}
41		CH ₃	H	CH ₃	H	80	0.45 ^{a)}
42		Cl	H	Cl	H	63	0.27 ^{c)}
43		CH ₃	H	CH ₃	H	57	0.24 ^{c)}
44		OCH ₃	H	OCH ₃	H	75	0.48 ^{a)}

Ex. No.	D	R ^I	R ^{II}	R ^{III}	R ^{IV}	Yield (% of th.)	R _f *
45		F	H	F	H	47	0.33 ^{b)}
46		Cl	H	H	Cl	60.5	0.42 ^{b)}
47		Cl	H	Cl	H	31	0.39 ^{b)}
48		Cl	H	H	Cl	50.5	0.23 ^{b)}
49		Cl	H	Cl	H	77	0.48 ^{a)}
50		Cl	H	Cl	H	81	0.42 ^{a)}
51		Cl	H	H	Cl	67.3	0.54 ^{a)}
52		Cl	H	H	Cl	93	0.41 ^{a)}
53		Cl	H	Cl	H	3.5	0.30 ⁱ⁾
54		Cl	H	Cl	H	17.4	0.22 ^{h)}
















Ex. No.	D	R ^I	R ^{II}	R ^{III}	R ^{IV}	Yield (% of th.)	R _f *
55		Cl	H	H	Cl	1.8	0.47 ¹⁾
56		Cl	H	H	Cl	4.1	0.28 ¹⁾
57		Cl	H	Cl	H	25.3	0.24 ¹⁾
58		Cl	H	Cl	H	16	0.39 ¹⁾
59		Cl	H	H	Cl	20.8	0.38 ¹⁾
60		Cl	H	H	Cl		

Table 2:


Ex.- No.	Structure	Yield (% of theory)	R _f *
61		49.6	0.54g)
62		7.1	0.28g)
63		72.5	0.45g)
64		21.6	0.49g)

65		21.3	0.46g
66		63.1	0.51g
67		38.7	0.48g
68		37.1	0.25g
69		57.9	0.27g

Ex.- No.	Structure	Yield (% of theory)	R _f *
70	 <chem>CCS(=O)(=O)Oc1ccc2c(c1)c(c[nH]2)C(=O)c3cc(C)c(C)cn3</chem>	21.6	0.25 ^{b)}
71	 <chem>Clc1ccc(cc1)S(=O)(=O)Oc2ccc3c(c2)c(c[nH]3)C(=O)c4cc(C)c(C)cn4</chem>	77.2	0.29 ^{b)}

We claim:

1. Benzofuranylsulfonates of the general formula (I)



5 in which

A represents hydrogen, straight-chain or branched acyl or alkoxycarbonyl, each having up to 6 carbon atoms, halogen, carboxyl, cyano, nitro, hydroxyl, trifluoromethyl or trifluoromethoxy, or straight-chain or
 10 branched alkyl having up to 6 carbon atoms, which is optionally substituted by carboxyl, alkoxy or alkoxycarbonyl each having up to 4 carbon atoms, phenoxy or benzoyl,

R¹ represents hydrogen, straight-chain or branched alkyl having up to 4
 15 carbon atoms, an amino protecting group or a group of the formula -CO-R⁵

in which

20 R⁵ denotes straight chain or branched alkoxy having up to 4 carbon atoms,

R² and R³ are identical or different and represent hydrogen, cycloalkyl having
 25 up to 6 carbon atoms, straight chain or branched alkyl, alkoxycarbonyl or alkenyl each having up to 8 carbon atoms,

or

R² and R³ together with the nitrogen atom form a 5- to 7-membered saturated heterocycle optionally having a further O atom,

R⁴ represents aryl having 6 to 10 carbon atoms or
5 represents a 5 to 7 membered, aromatic, saturated or unsaturated heterocycle, which can contain up to 3 oxygen, sulphur and/or nitrogen atoms as heteroatoms or a residue of a formula -NR⁶,

wherein

10 R⁶ denotes hydrogen or straight-chain or branched alkyl or alkoxy carbonyl each having up to 6 carbon atoms,

15 and to which further a benzene ring can be fused and wherein aryl and/or the heterocycle are optionally monosubstituted to trisubstituted by identical or different substituents from the series comprising hydroxyl, halogen, nitro, 1H-tetrazolyl, pyridyl, trifluoromethyl, trifluoromethoxy, difluoromethyl, difluoromethoxy, cyano, carboxy, straight-chain or branched alkoxy, alkoxy carbonyl or acyl each having
20 up to 6 carbon atoms or by straight-chain or branched alkyl having up to 5 carbon atoms, which is optionally substituted by carboxyl or straight-chain or branched alkoxy carbonyl having up to 4 carbon atoms or by a group of formula -NR⁷R⁸, -SR⁹, -(NH)_a-SO₂R¹⁰ or -O-SO₂R¹¹,

25 in which

R⁷ and R⁸ are identical or different and denote hydrogen or a straight-chain or branched alkyl having up to 4 carbon atoms,

30 or

R^7 denotes hydrogen

and

5 R^8 denotes straight-chain or branched acyl having up to 6 carbon atoms

R^9 denotes hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms,

10


a denotes a number 0 or 1,

R^{10} and R^{11} are identical or different and represent straight-chain or branched alkyl having up to 6 carbon atoms, benzyl or phenyl, which are optionally substituted by trifluoromethyl, halogen or straight-chain or branched alkyl having up to 4 carbon atoms,

15

L represents an oxygen or sulfur atom,

20 D represents a residue of a formula



25 or aryl having 6 to 10 carbon atoms or a 5 to 7-membered aromatic, saturated or unsaturated heterocycle having up to 3 heteroatoms from the series comprising N, S and O and to which a phenyl ring can be fused, wherein all abovementioned residues and ring systems are

optionally monosubstituted to trisubstituted by halogen, carboxyl, straight-chain or branched alkyl or alkoxycarbonyl each having up to 6 carbon atoms, pyridyl and/or by a residue of a formula $-NR^{12}-E-R^{13}$, $-NR^{14}-CO-NR^{15}R^{16}$, $-NR^{17}-SO_2-NR^{18}R^{19}$, $-SO_2-R^{20}$ or $-(SO_2)_b-NR^{21}R^{22}$,

5

wherein

b denotes a number 0 or 1,

10

E denotes a residue of formula SO_2 or CO

R^{12} , R^{14} , R^{15} , R^{16} , R^{17} , R^{18} , R^{19} , R^{21} and R^{22} are identical or different and denote hydrogen, phenyl or straight-chain or branched alkyl having up to 6 carbon atoms,

15

R^{13} denotes straight-chain or branched alkyl or alkoxy each having up to 6 carbon atoms,


20

R^{20} denotes benzyl, phenyl, pyridyl or straight-chain or branched alkyl having up to 6 carbon atoms,

or

25

D represents straight-chain or branched alkyl or alkenylen having up to 8 carbon atoms, which are monosubstituted to trisubstituted by halogen, aryl having 6 to 10 carbon atoms or a 5 to 7-membered saturated or unsaturated heterocycle having up to 3 heteroatoms from the series comprising N, S and O and to which a phenyl ring can be fused or by a residue of a formula $-NR^{23}R^{24}$ or



wherein

5 R^{23} and R^{24} have the abovementioned meaning of R^{15} and R^{16} and are identical or different to the latter,

wherein the abovementioned ring systems are optionally substituted by halogen,

10 and in the case that

R^4 does not represent phenyl or substituted phenyl,

15 D in addition can represent benzyl or straight-chain or branched alkyl having up to 5 carbon atoms,

or

20 D optionally represents a residue of a formula $-NR^{25}R^{26}$

wherein

R^{25} and R^{26} have the abovementioned meaning of R^{21} and R^{22} and are identical or different to the latter,

25

and salts thereof.


2. Compounds according to claim 1, in which

- 5 A represents hydrogen, halogen, carboxyl, cyano, nitro, hydroxyl, trifluoromethyl, trifluoromethoxy or alkoxy having up to 4 carbon atoms
- R¹ represents hydrogen, straight-chain or branched alkyl having up to 4 carbon atoms or a group of the formula -CO-R⁵
- in which
- 10 R⁵ denotes straight chain or branched alkoxy having up to 4 carbon atoms,
- 15 R² and R³ are identical or different and represent hydrogen, cyclobutyl, cyclopentyl, cyclohexyl or straight-chain or branched alkyl, alkoxy-carbonyl or alkenyl each having up to 4 carbon atoms, or
- or
- 20 R² and R³ together with the nitrogen atom form a pyrrolidinyl-, piperidinyl- or morpholinyl-ring,
- and
- 25 R⁴ represents phenyl, pyridyl or thienyl, wherein all rings are optionally monosubstituted to trisubstituted by identical or different substituents from the series comprising hydroxyl, fluorine, chlorine, bromine, nitro, carboxy, straight-chain or branched alkoxy, alkoxycarbonyl or acyl each having up to 3 carbon atoms, or by straight-chain or branched alkyl
- 30 having up to 3 carbon atoms, which is optionally substituted by

carboxyl or straight-chain or branched alkoxycarbonyl having up to 3 carbon atoms

L represents an oxygen or sulfur atom,

D represents a residue of a formula



or phenyl, pyridyl, thienyl, furyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, imidazolyl, morpholinyl, piperidinyl, pyrrolidinyl or piperazinyl, wherein all abovementioned residues and ring systems are optionally monosubstituted to trisubstituted by halogen, carboxyl, straight-chain or branched alkyl or alkoxycarbonyl each having up to 4 carbon atoms, pyridyl and/or by a residue of a formula $-NR^{12}-E-R^{13}$, $-NR^{14}-CO-NR^{15}R^{16}$, $-NR^{17}-SO_2-NR^{18}R^{19}$, $-SO_2-R^{20}$ or $-(SO_2)_b-NR^{21}R^{22}$,

wherein

b denotes a number 0 or 1,

E denotes a residue of formula SO_2 or CO

R^{12} , R^{14} , R^{15} , R^{16} , R^{17} , R^{18} , R^{19} , R^{21} and R^{22} are identical or different and denote hydrogen, phenyl or straight-chain or branched alkyl having up to 4 carbon atoms,

R^{13} denotes straight-chain or branched alkyl or alkoxy each having up to 4 carbon atoms,


R^{20} denotes benzyl, phenyl, pyridyl, ethyl or methyl,

5

or

D represents straight-chain or branched alkyl or alkenylen having up to 6 carbon atoms, which are monosubstituted to trisubstituted by halogen, phenyl, pyridyl, thienyl, furyl, imidazolyl, morpholinyl, piperidinyl, pyrrolidinyl, piperazinyl or by a residue of a formula $-NR^{23}R^{24}$ or

10



wherein

R^{23} and R^{24} have the abovementioned meaning of R^{15} and R^{16} and are identical or different to the latter,

15

wherein the abovementioned ring systems are optionally substituted by halogen,

20

and in the case that

R^4 does not represent phenyl or substituted phenyl,

25

D additionally can represent benzyl or straight-chain or branched alkyl having up to 4 carbon atoms,

or

D optionally represents a residue of a formula $-NR^{25}R^{26}$

wherein

5

R^{25} and R^{26} have the abovementioned meaning of R^{21} and R^{22} and are identical or different to the latter

and salts thereof.

10

3. Compounds according to claim 1 or 2, in which

A, R^2 and R^3 represent hydrogen,

15

R^1 represents hydrogen or straight-chain or branched alkyl having up to 3 carbon atoms or a group of the formula $-CO-R^5$,

in which

20


R^5 denotes straight chain or branched alkoxy having up to 3 carbon atoms,

R^4 represents phenyl or pyridyl, which are optionally up to difold substituted by identical or different substituents from the series fluorine, chlorine, methyl or methoxy,

25

L represents an oxygen atom,

D represents a residue of a formula



or phenyl, pyridyl, thienyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, imidazolyl, morpholinyl, piperidinyl, pyrrolidinyl or piperazinyl, wherein all abovementioned residues and ring systems are optionally monosubstituted to trisubstituted by halogen, carboxyl, straight-chain or branched alkyl or alkoxy carbonyl each having up to 3 carbon atoms, pyridyl and/or by a residue of a formula $-NR^{12}-E-R^{13}$, $-NR^{14}-CO-NR^{15}R^{16}$, $-NR^{17}-SO_2-NR^{18}R^{19}$, $-SO_2-R^{20}$ or $-(SO_2)_b-NR^{21}R^{22}$,

wherein

b denotes a number 0 or 1,

E denotes a residue of formula SO_2 or CO

R^{12} , R^{14} , R^{15} , R^{16} , R^{17} , R^{18} , R^{19} , R^{21} and R^{22} are identical or different and denote hydrogen, phenyl or straight-chain or branched alkyl having up to 3 carbon atoms,


R^{13} denotes straight-chain or branched alkyl or alkoxy each having up to 3 carbon atoms,

R^{20} denotes benzyl, phenyl or methyl,

or

D represents straight-chain or branched alkyl or alkenylen having up to 4 carbon atoms, which are monosubstituted to trisubstituted by halogen, phenyl, pyridyl, thienyl, furyl, imidazolyl, morpholinyl, piperidinyl, pyrrolidinyl, piperazinyl or by a residue of a formula $-NR^{23}R^{24}$ or

5



wherein

10

R^{23} and R^{24} have the abovementioned meaning of R^{15} and R^{16} and are identical or different to the latter,

wherein the abovementioned ring systems are optionally substituted by halogen,

15

and in the case that

R^4 does not represent phenyl or substituted phenyl,

20

D additionally can represent benzyl or straight-chain or branched alkyl having up to 3 carbon atoms,

or

25

D optionally represents a residue of a formula $-NR^{25}R^{26}$


wherein

R^{25} and R^{26} have the abovementioned meaning of R^{21} and R^{22} and are identical or different to the latter

and salts thereof.

5

4. A process for the preparation of the compounds according to any one of claims 1 to 3, characterized in that compounds of the general formula (II)




10

in which

A, L, R^1 , R^2 , R^3 and R^4 have the abovementioned meaning

are reacted with compounds of the general formula (III)

15



in which

D has the abovementioned meaning,

20

in inert solvents, if appropriate in the presence of a base and/or in the presence of an auxiliary.

25

5. Benzofuranylsulfonates according to any one of claims 1 to 3 for therapeutic use.

6. The composition containing at least one Benzofuranylsulfonate according to any one of claims 1 to 3 and a pharmacologically acceptable diluent.
- 5 7. A composition according to claim 6 for the treatment and prevention of acute and chronic inflammatory processes.
8. The process for the preparation of compositions according to claim 6 and 7, characterized in that the Benzofuranylsulfonate together with customary auxiliaries is brought into a suitable application form.
- 10 9. Use of Benzofuranylsulfonates according to any one of claims 1 to 3 for the preparation of medicaments.
- 15 10. Use according to claim 9 for the preparation of medicaments for the treatment and prevention of acute and chronic inflammatory processes.

INTERNATIONAL SEARCH REPORT

Int: l: tional Application No
PCT/EP 00/04010

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C07D307/82 A61K31/34 A61P29/00		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07D A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 779 291 A (BAYER AG) 18 June 1997 (1997-06-18) claims 1-10	1-10
Y	WO 98 02440 A (BAYER AG) 22 January 1998 (1998-01-22) claims 1-10	1-10
Y	EP 0 731 099 A (BAYER AG) 11 September 1996 (1996-09-11) cited in the application claims 1-10	1-10
Y	EP 0 146 243 A (MERCK FROSST CANADA INC.) 26 June 1985 (1985-06-26) claims 1-37	1-10
	-/--	
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family		
Date of the actual completion of the international search 18 August 2000		Date of mailing of the international search report 29/08/2000
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer Herz, C

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 00/04010

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 623 607 A (BAYER AG) 9 November 1994 (1994-11-09) claims 1-9	1-10
Y	EP 0 685 479 A (BAYER AG) 6 December 1995 (1995-12-06) claims 1-10	1-10

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. l. Application No

PCT/EP 00/04010

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 779291 A	18-06-1997	CA 2192281 A JP 9202785 A US 5922740 A	12-06-1997 05-08-1997 13-07-1999
WO 9802440 A	22-01-1998	AU 3441197 A EP 0912578 A	09-02-1998 06-05-1999
EP 731099 A	11-09-1996	AT 193704 T AU 705667 B AU 4582896 A BG 100396 A BR 9600930 A CA 2170824 A CN 1134419 A CZ 9600667 A DE 69608721 D FI 960998 A HR 960071 A HU 9600549 A JP 8253466 A NO 960884 A NZ 286107 A PL 313070 A SK 29796 A TR 960863 A ZA 9601774 A	15-06-2000 27-05-1999 19-09-1996 31-12-1996 30-12-1997 07-09-1996 30-10-1996 11-09-1996 13-07-2000 07-09-1996 31-12-1997 28-07-1997 01-10-1996 09-09-1996 26-08-1998 16-09-1996 01-10-1996 21-10-1996 17-09-1996
EP 146243 A	26-06-1985	CA 1281329 A JP 60112783 A US 4745127 A US 4822803 A US 4933351 A US 4663347 A	12-03-1991 19-06-1985 17-05-1988 18-04-1989 12-06-1990 05-05-1987
EP 623607 A	09-11-1994	AT 168373 T AU 678814 B AU 6055894 A CA 2122788 A CN 1097749 A CZ 9401129 A DE 69411625 D DE 69411625 T ES 2118283 T FI 942049 A GR 3027787 T HU 67847 A JP 6329652 A NO 941662 A NZ 260445 A RU 2125564 C SK 53194 A US 5504213 A ZA 9403100 A	15-08-1998 12-06-1997 10-11-1994 07-11-1994 25-01-1995 16-11-1994 20-08-1998 05-11-1998 16-09-1998 07-11-1994 30-11-1998 29-05-1995 29-11-1994 07-11-1994 28-08-1995 27-01-1999 08-02-1995 02-04-1996 09-01-1995
EP 685479 A	06-12-1995	AT 175671 T CA 2150305 A DE 69507199 D DE 69507199 T	15-01-1999 01-12-1995 25-02-1999 27-05-1999

Information on patent family members

PCT/EP 00/04010

Form PCT/ISA/210 (patent family annex) (July 1992)